Radiological differentiation of phaeochromocytoma from other malignant adrenal masses: importance of wash-in characteristics on multiphase CECT.
multiphase CECT
peak arterial enhancement
percentage arterial enhancement
phaeochromocytoma
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
received:
20
05
2019
accepted:
05
06
2019
entrez:
29
6
2019
pubmed:
30
6
2019
medline:
30
6
2019
Statut:
ppublish
Résumé
To evaluate the computerised tomography (CT) characteristics of phaeochromocytoma (PCC) that differentiate them from other non-benign adrenal masses such as adrenocortical carcinoma (ACC), primary adrenal lymphoma (PAL) and adrenal metastases (AM). This retrospective study was conducted at a tertiary health care institute from Western India. Patients presented between January 2013 and August 2016 with histological diagnosis of PCC or other non-benign adrenal mass having adequate reviewable imaging data comprising all four CECT phases were included. The study cohort consisted of 72 adrenal masses from 66 patients (33 PCC, 22 ACC, 4 PAL, 13 AM). Unlike other masses, majority of PCC (25/33) showed peak enhancement in early arterial phase (EAP). PCC had significantly higher attenuation in EAP and early venous phase (EVP), and higher calculated percentage arterial enhancement (PAE) and percentage venous enhancement (PVE) than other adrenal masses (P < 0.001). For diagnosis of PCC with 100% specificity, PAE value ≥100% and EAP attenuation ≥100 HU had 78.8 and 63.6% sensitivity respectively. ACC were significantly larger in size as compared to PCC and metastasis. The adreniform shape was exclusively found in PAL (two out of four) and AM (4 out of 13). None of the enhancement, wash-in or washout characteristics were discriminatory among ACC, PAL and AM. Peak enhancement in EAP, PAE value ≥100% and EAP attenuation ≥100 HU differentiate PCC from other malignant adrenal masses with high specificity.
Identifiants
pubmed: 31252396
doi: 10.1530/EC-19-0198
pii: EC-19-0198
pmc: PMC6599213
doi:
pii:
Types de publication
Journal Article
Langues
eng
Pagination
898-905Références
Nan Fang Yi Ke Da Xue Xue Bao. 2015 Dec;35(12):1792-6
pubmed: 26714918
Best Pract Res Clin Endocrinol Metab. 2010 Dec;24(6):957-68
pubmed: 21115164
AJR Am J Roentgenol. 2013 Oct;201(4):834-9
pubmed: 24059372
Radiology. 2010 Jul;256(1):32-61
pubmed: 20574084
AJR Am J Roentgenol. 2010 Jun;194(6):1484-91
pubmed: 20489087
Radiology. 1998 May;207(2):369-75
pubmed: 9577483
Radiology. 2007 Dec;245(3):788-97
pubmed: 18024453
Eur J Endocrinol. 2016 Aug;175(2):G1-G34
pubmed: 27390021
Abdom Radiol (NY). 2017 Sep;42(9):2305-2313
pubmed: 28357529
Radiology. 2005 Feb;234(2):479-85
pubmed: 15671003
Radiology. 2009 Feb;250(2):474-81
pubmed: 19037020
Br J Radiol. 2011 Dec;84 Spec No 2:S112-20
pubmed: 22433822
Eur J Endocrinol. 2016 Aug;175(2):R51-64
pubmed: 27257145
Radiographics. 2004 Oct;24 Suppl 1:S87-99
pubmed: 15486252
Radiology. 2010 Aug;256(2):504-10
pubmed: 20656838